Amit Singal, MD MS
Dr. Amit G. Singal, MD MS is an Associate Professor of Medicine at UT Southwestern Medical Center. He is an expert in hepatocellular carcinoma, particularly in early tumor detection and screening process failures, and serves as Chief of Hepatology. He currently is leading several NIH and CPRIT funded projects to evaluate interventions to improve the effectiveness of early tumor detection, treatment, and overall prognosis among patients with cirrhosis in the United States, and he has published over 100 scientific papers on these topics. He is involved in several professional societies, including being on the governing board of the International Liver Cancer Association and serving as the vice chair of the AASLD practice guidelines committee.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BayerDate added:Date updated:06/10/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:EisaiDate added:Date updated:06/10/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ExelixisDate added:Date updated:06/10/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GenentechDate added:Date updated:06/10/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:RocheDate added:Date updated:06/10/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GlycotestDate added:Date updated:06/10/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Exact SciencesDate added:Date updated:06/10/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GRAILDate added:Date updated:06/10/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Wako DiagnosticsDate added:Date updated:06/10/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstraZenecaDate added:12/06/2021Date updated:06/10/2024